Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABTHER is an antimalarial injection containing alpha-beta arteether (artemotil), a semi-synthetic derivative of artemisinin. Developed by Greenlife Pharmaceuticals and manufactured by Indasi Lifescience, it is indicated for the treatment of severe malaria, including cerebral malaria. The mechanism of action involves the cleavage of the drug's internal endoperoxide bridge by heme-iron within the parasite's food vacuole, generating reactive free radicals that alkylate and damage essential parasitic proteins and lipids. It is specifically formulated as an oily solution for intramuscular administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ABTHER.